These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28825695)

  • 1. Augmenter of liver regeneration potentiates doxorubicin anticancer efficacy by reducing the expression of ABCB1 and ABCG2 in hepatocellular carcinoma.
    Guo YY; Wu Y; Jia XW; An W
    Lab Invest; 2017 Dec; 97(12):1400-1411. PubMed ID: 28825695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver regeneration associated protein (ALR) exhibits antimetastatic potential in hepatocellular carcinoma.
    Dayoub R; Wagner H; Bataille F; Stöltzing O; Spruss T; Buechler C; Schlitt HJ; Weiss TS
    Mol Med; 2011; 17(3-4):221-8. PubMed ID: 21152698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells.
    Yin W; Xiang D; Wang T; Zhang Y; Pham CV; Zhou S; Jiang G; Hou Y; Zhu Y; Han Y; Qiao L; Tran PH; Duan W
    Sci Rep; 2021 May; 11(1):10791. PubMed ID: 34031441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
    Hou H; Sun H; Lu P; Ge C; Zhang L; Li H; Zhao F; Tian H; Zhang L; Chen T; Yao M; Li J
    Mol Cancer Ther; 2013 Dec; 12(12):2874-84. PubMed ID: 24130050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
    Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells.
    Jegal ME; Jung SY; Han YS; Kim YJ
    BMB Rep; 2019 May; 52(5):330-335. PubMed ID: 30982500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo.
    Chen Z; Chen Y; Xu M; Chen L; Zhang X; To KK; Zhao H; Wang F; Xia Z; Chen X; Fu L
    Mol Cancer Ther; 2016 Aug; 15(8):1845-58. PubMed ID: 27196753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function.
    Robinson AN; Tebase BG; Francone SC; Huff LM; Kozlowski H; Cossari D; Lee JM; Esposito D; Robey RW; Gottesman MM
    Drug Metab Dispos; 2019 Jul; 47(7):715-723. PubMed ID: 31048454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.
    Sukowati CH; Rosso N; Pascut D; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
    BMC Gastroenterol; 2012 Nov; 12():160. PubMed ID: 23153066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of augmenter of liver regeneration (ALR) in human liver cirrhosis and carcinoma.
    Thasler WE; Schlott T; Thelen P; Hellerbrand C; Bataille F; Lichtenauer M; Schlitt HJ; Jauch KW; Weiss TS
    Histopathology; 2005 Jul; 47(1):57-66. PubMed ID: 15982324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver-specific deletion of augmenter of liver regeneration accelerates development of steatohepatitis and hepatocellular carcinoma in mice.
    Gandhi CR; Chaillet JR; Nalesnik MA; Kumar S; Dangi A; Demetris AJ; Ferrell R; Wu T; Divanovic S; Stankeiwicz T; Shaffer B; Stolz DB; Harvey SA; Wang J; Starzl TE
    Gastroenterology; 2015 Feb; 148(2):379-391.e4. PubMed ID: 25448926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma.
    Zheng M; Ai Z; Guo Y; Chen Y; Xie P; An W
    Oncogene; 2023 Jan; 42(4):308-321. PubMed ID: 36434180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells.
    Karaosmanoğlu O; Banerjee S; Sivas H
    Cell Oncol (Dordr); 2018 Aug; 41(4):439-453. PubMed ID: 29858962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.